Sharemaestro company-news research for Braveheart Bio, Inc. Common Stock (BRVE), showing current tone, evidence confidence, direct company coverage, sector and industry context, completed price response and the source headlines used on the page. Scores describe published news evidence. Confidence describes the amount, freshness, source breadth and direct company relevance of that evidence. Price context is shown separately.

NASDAQ United States Provisional evidence

Company news sentiment

Latest BRVE news and sentiment

Braveheart Bio, Inc. Common Stock

Company headlines from the last 30 days, weighted by freshness, relevance, publisher quality and the strength of the wording. Price is shown separately.

Full chart Weekly report Factor research RSS feed
Latest weekly closeUSD 20.02week of 9 Oct 2026
Main news subjectMarket update85/100 share of current news
News data statusHealthy21 duplicate stories removed

Current company news

Early balanced news score

9 company-specific stories are available, but there are not yet enough fresh stories from separate publishers for a firm reading.

Observed headline tone69/100 Published 30-day score50/100

Older, less relevant and less reliable stories count for less. Confidence is shown separately.

Latest source headline Braveheart Bio, Inc. Common Stock (NASDAQ: BRVE) Stock Price, News & Analysis Kalkine · 06 Oct 2026 22:40

What supports the score

Direct evidence

9 current stories are mapped specifically to BRVE.

What limits the score

Source breadth

Only 1 publisher currently contribute to the measured read.

Too little evidence

The stories agree, but freshness-weighted evidence is only 0.001.

Confidence

Confidence is 15/100, below the threshold for a firm score.

50/100
News scoreEarly balanced news score
15/100
Confidencethin evidence
100%/100
Company news9 company stories
100/100
Story agreement0/100 difference

News history

Daily score and story count over 30 days

Daily weighted evidence · gaps mean no reading
21 Sep: 1 stories22 Sep: 1 stories23 Sep: 1 stories25 Sep: 2 stories29 Sep: 1 stories01 Oct: 1 stories06 Oct: 1 stories 21 Sep: tone 44, 1 stories22 Sep: tone 50, 1 stories23 Sep: tone 50, 1 stories25 Sep: tone 56, 2 stories29 Sep: tone 50, 1 stories01 Oct: tone 69, 1 stories06 Oct: tone 50, 1 stories 100500
17 Sep02 Oct16 Oct
News scoreStory count50 baseline

Confidence

How reliable the score is

Separate from direction

Confidence uses the amount of news, separate publishers, direct company relevance, freshness and agreement. A high or low score is not automatically reliable.

Amount of evidence0
0.001 after freshness weighting
Source breadth20
1 independent publishers
Company relevance100
share tied directly to this company
Freshness7
recency-weighted evidence
Agreement100
how closely stories agree
Publisher mix0
less reliance on one publisher

Price and news history

Weekly price and news-score history

Early company-news score

Company-specific news is present, but the evidence has not yet earned enough independent, fresh information weight for price confirmation to be treated as a firm signal.

10 completed price weeks10 comparable news-score weeks
One scoring method across the chart.Stored company headlines are recalculated at each weekly point with the current 30-day freshness weighting. Old published snapshots are left unchanged.
07 Aug 2026: close 30.0, indexed 100.014 Aug 2026: close 27.03, indexed 90.121 Aug 2026: close 27.58, indexed 91.928 Aug 2026: close 27.44, indexed 91.504 Sep 2026: close 26.74, indexed 89.111 Sep 2026: close 26.64, indexed 88.818 Sep 2026: close 29.2, indexed 97.325 Sep 2026: close 20.62, indexed 68.702 Oct 2026: close 21.27, indexed 70.909 Oct 2026: close 20.02, indexed 66.7 07 Aug 2026: news score 59, close 30.0, 14 stories5914 Aug 2026: news score 51, close 27.03, 28 stories21 Aug 2026: news score 50, close 27.58, 31 stories5028 Aug 2026: news score 50, close 27.44, 32 stories04 Sep 2026: news score 55, close 26.74, 38 stories5511 Sep 2026: news score 47, close 26.64, 29 stories18 Sep 2026: news score 51, close 29.2, 25 stories5125 Sep 2026: news score 48, close 20.62, 29 stories02 Oct 2026: news score 51, close 21.27, 23 stories5109 Oct 2026: news score 50, close 20.02, 11 stories50 Price index 104.0 83.4 62.7 News score 100 50 0
07 Aug08 Sep09 Oct
Weekly close, indexedSentiment score
26-week price-33.3%latest close 20.02
News score change-9first to latest comparable week
One-week response-5.9%Price reacting lower
Fair-value position-22.0%Below fair value
WeekNews scoreCloseWeekly move
09 Oct 202650USD 20.02-5.9%
02 Oct 202651USD 21.27+3.2%
25 Sep 202648USD 20.62-29.4%
18 Sep 202651USD 29.2+9.6%
11 Sep 202647USD 26.64-0.4%
04 Sep 202655USD 26.74-2.6%
28 Aug 202650USD 27.44-0.5%
21 Aug 202650USD 27.58+2.0%
Provisional evidence

News subjects

What is shaping the score

Market update
Market update567 stories · 78%
Analyst action561 stories · 11%
Earnings501 stories · 11%

Source mix

Where the evidence comes from

0/100 independence
MarketBeat555 stories · 56%
Kalkine501 stories · 11%
Market source501 stories · 11%
bnnbloomberg.ca501 stories · 11%
The Manila Times501 stories · 11%

Recurring subjects

Subjects appearing most often

Current evidence
Life Sciences7Financial Markets6Earnings5Finance3Clinical Trials1Cardiovascular1Biopharmaceuticals1

Earlier readings

How the score has changed

23 comparable readings · 70 days
Past and present use the same method.Each point recalculates the previous 30 days of stored company headlines with today's scoring rules. The original stored snapshots remain unchanged.
Comparable move-959 to 50 · Weakening
Observed range46–5950 is the neutral baseline
Evidence depth9stories at latest stored reading · -5
Confidence16/100Provisional · -17
07 Aug50 neutral16 Oct 15:40
ConstructiveBalanced or withheldCautious

Changes in the stored score

Scores are rebuilt from stored headlines with the current 30-day method. Days with no change are collapsed.

ObservedScoreMoveConfidenceStoriesStatus
16 Oct 15:4050+016/100 (-3)9 (-15)Provisional
06 Oct 23:5950-119/100 (-10)24 (+1)Provisional
01 Oct 23:5951+229/100 (+9)23 (-7)Provisional
29 Sep 23:5949+120/100 (-4)30 (+1)Provisional
25 Sep 23:5948+024/100 (-3)29 (+2)Provisional
23 Sep 23:5948+027/100 (-1)27 (+1)Provisional
22 Sep 23:5948+028/100 (-2)26 (0)Provisional
21 Sep 23:5948-330/100 (0)26 (-2)Provisional

Evidence behind the direction

What drives this reading?

1 directional stories · 1 publisher groups

Shares of weighted directional evidence in 9 retained current headlines. These weights already account for freshness, relevance and publisher limits; they are not additive points of the published score.

Which subjects lean each way

A subject can carry both supportive and cautious news.

SubjectCautious ← 0 → Constructive
Market update1 story
0.0%100.0%

Each side uses the same scale: 0–100.0% of the retained directional evidence.

Where the influence comes from

100.0%largest publisher share

A concentrated reading can depend heavily on one publisher.

MarketBeat1 story100.0%

Publisher groups follow the scoring rules. Company disclosures share one group; syndicated stories are consolidated before weighting.

Source headlines

The news behind the score

Showing 1-9 of 9

Only company-specific stories enter this score. The latest 30 days are shown newest first, with newer stories weighted more heavily and duplicate coverage combined.

Kalkine
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
06 Oct 2026 22:40
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 9.7d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
MarketBeat
69/100 tone

Braveheart Bio (NASDAQ: BRVE) shares rose 8.1% to $21.84, despite trading volume being 83% below average. Analysts generally have a positive outlook, with five "Buy" ratings and one "Hold" rating, and a consensus price target of $45.25. The company missed its quarterly earnings estimate s…

100% of directional evidence Medium story strength
Scoring detailsDirect company coverage

Braveheart Bio (NASDAQ: BRVE) shares rose 8.1% to $21.84, despite trading volume being 83% below average. Analysts generally have a positive outlook, with five "Buy" ratings and one "Hold" rating, and a consensus price target of $45.25. The company missed its quarterly earnings estimate significantly, reporting a loss of $2.51 per share against an estimated $0.25, but insiders have recently purchased a substantial amount of shares, totaling $157.5 million.

Published
01 Oct 2026 18:59
News subject
Market update
Why this score
Positive market reaction, Large positive market reaction
Company focus
Main company · 100%
How it is used
Direct company coverage
Story strength
Medium · 47/100
30-day weight
100% of directional evidence · 14.9d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
EarningsFinancial MarketsLife Sciences
MarketBeat
—Unscored

Braveheart Bio, Inc. (NASDAQ:BRVE) experienced a significant surge in short interest in September, increasing by 76.1% to 2.46 million shares. This represents 2.7% of shares outstanding and a days-to-cover ratio of 7.5 days. Despite a recent quarterly EPS miss, insiders have been actively…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Braveheart Bio, Inc. (NASDAQ:BRVE) experienced a significant surge in short interest in September, increasing by 76.1% to 2.46 million shares. This represents 2.7% of shares outstanding and a days-to-cover ratio of 7.5 days. Despite a recent quarterly EPS miss, insiders have been actively purchasing shares, acquiring over 8.75 million shares worth approximately $157.5 million in the last 90 days, and analysts maintain a "Moderate Buy" rating with an average price target of $45.25.

Published
29 Sep 2026 17:25
News subject
Market update
Why this score
Positive financial language
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 16.9d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
EarningsFinanceFinancial MarketsLife Sciences
Market source
—Unscored

This page provides an interactive stock chart for Braveheart Bio, Inc. (BRVE). The stock closed at $20.62, down 11.77%, and was trading at $21.08 in after-hours, up 2.21%. The chart allows users to select various time ranges and intervals to analyze the stock's performance.

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

This page provides an interactive stock chart for Braveheart Bio, Inc. (BRVE). The stock closed at $20.62, down 11.77%, and was trading at $21.08 in after-hours, up 2.21%. The chart allows users to select various time ranges and intervals to analyze the stock's performance.

Published
25 Sep 2026 10:51
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.2d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
Financial MarketsLife Sciences
MarketBeat
—Unscored

Braveheart Bio, Inc. (NASDAQ:BRVE) has received an average "Moderate Buy" recommendation from analysts, with five out of six firms issuing a buy rating and an average 12-month price target of $45.25. Despite a significant earnings miss in the last quarter, insider buying has been substant…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Braveheart Bio, Inc. (NASDAQ:BRVE) has received an average "Moderate Buy" recommendation from analysts, with five out of six firms issuing a buy rating and an average 12-month price target of $45.25. Despite a significant earnings miss in the last quarter, insider buying has been substantial, with directors purchasing millions of shares totaling approximately $157.5 million. The company is a clinical-stage biopharmaceutical firm focused on therapies for hypertrophic cardiomyopathy, with its lead product candidate, BHB‑1893, being developed for obstructive and non‑obstructive HCM.

Published
25 Sep 2026 09:54
News subject
Analyst action
Why this score
Buy Rating
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 21.2d old
Text assessed
Available headline and article text
Duplicates
2 consolidated
EarningsFinanceFinancial MarketsLife Sciences
bnnbloomberg.ca
—Unscored
Company news retained for context; no directional weight.
Scoring detailsDirect company coverage
Published
23 Sep 2026 23:13
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 22.7d old
Text assessed
Stored headline only
Duplicates
1 consolidated
MarketBeat
—Unscored

Braveheart Bio (NASDAQ:BRVE) recently hit a new 52-week low of $24.17 after reporting significantly weaker-than-expected quarterly earnings. Despite the poor earnings performance, analysts maintain a "Moderate Buy" rating with an average price target of $45.25. Insider activity shows stro…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Braveheart Bio (NASDAQ:BRVE) recently hit a new 52-week low of $24.17 after reporting significantly weaker-than-expected quarterly earnings. Despite the poor earnings performance, analysts maintain a "Moderate Buy" rating with an average price target of $45.25. Insider activity shows strong buying interest, with directors acquiring substantial shares in the last 90 days.

Published
22 Sep 2026 16:34
News subject
Earnings
Why this score
Positive financial language
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 24.0d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
EarningsFinancial MarketsLife Sciences
MarketBeat
—Unscored

Braveheart Bio (NASDAQ:BRVE) shares dropped 6.6% to $27.26 on Monday, with trading volume significantly below average. Despite a substantial earnings miss, analysts maintain a "Moderate Buy" consensus with an average price target of $45.25. Insider buying totaling $157.5 million over the …

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Braveheart Bio (NASDAQ:BRVE) shares dropped 6.6% to $27.26 on Monday, with trading volume significantly below average. Despite a substantial earnings miss, analysts maintain a "Moderate Buy" consensus with an average price target of $45.25. Insider buying totaling $157.5 million over the last three months suggests confidence in the company's future.

Published
21 Sep 2026 16:46
News subject
Market update
Why this score
Negative market reaction, Large negative market reaction
Company focus
Main company · 100%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 25.0d old
Text assessed
Available headline and article text
Duplicates
1 consolidated
EarningsFinancial MarketsLife Sciences
The Manila Times
—Unscored

Braveheart Bio, Inc. announced its participation in the Stifel Virtual Cardiometabolic Forum on September 30, 2026. Management will host a fireside chat at 12:30 p.m. EDT, which can be accessed via a live webcast on their investor relations website. The company is a clinical-stage biophar…

Company news retained for context; no directional weight.
Scoring detailsDirect company coverage

Braveheart Bio, Inc. announced its participation in the Stifel Virtual Cardiometabolic Forum on September 30, 2026. Management will host a fireside chat at 12:30 p.m. EDT, which can be accessed via a live webcast on their investor relations website. The company is a clinical-stage biopharmaceutical firm focusing on treatments for hypertrophic cardiomyopathy and other cardiovascular diseases, with its lead candidate BHB-1893 targeting obstructive and non-obstructive HCM.

Published
16 Sep 2026 20:58
News subject
Market update
Why this score
No clear directional signal in the available text
Company focus
Shared story · 78%
How it is used
Shown as company news · not used in the score
Story strength
Not directional
30-day weight
None · 29.8d old
Text assessed
Available headline and article text
Duplicates
3 consolidated
BiopharmaceuticalsCardiovascularClinical TrialsFinanceLife Sciences

Earlier company news

BRVE news archive

54 older headlines

Stored newest first for historical research. It starts after the newest three pages above and then continues through older news. Each archive page is loaded only when it is opened.

Older news is kept in the archive

There are 54 older BRVE headlines. Open one page at a time when you need them.

Open older archive

Provider matches checked

Provider mentions not used in the score

7 not scored

A news provider linked these stories to BRVE, but the headline and available text are not mainly about Braveheart Bio, Inc. Common Stock. They are kept here for transparency and do not affect the score, confidence, history or wider market totals.

Provider mentions are kept separate

Open the list to see which provider matches were checked and left out of BRVE sentiment.

Open provider mentions

How the page works

How to read the score

The score shows direction

It describes the weighted balance of qualifying headlines. A score of 50 can mean balanced news or that there is not enough evidence; the status label explains which.

Confidence is separate

Confidence measures depth, source breadth, direct relevance, freshness and agreement. It does not rise merely because the tone is extreme. This is a rule-based evidence measure, not a calibrated probability.

Price is confirmation

Weekly price response, trend and fair-value position test whether the market is accepting or rejecting the news. They never rewrite the news score.

What the page does

It measures news already published. It is not a forecast, recommendation or price target.

Evidence context